Abstract
The BNT162b2 mRNA vaccine from Pfizer–BioNTech1 and the ChAdOx1 nCoV-19 vaccine from Oxford–AstraZeneca2 were the first two products deployed in the UK's COVID-19 vaccination programme. In accordance with the strategy set by the nation's Joint Committee on Vaccination and Immunisation (JCVI), vaccines were initially prioritised for care home residents and staff, individuals older than 80 years, and front-line health-care and social care workers. In December, 2020, in response to surging transmission of SARS-CoV-2, JCVI advised delaying the second dose of these vaccines to achieve broader population coverage with the first dose.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
